Erasmus MC-Sophia Children's hospital
Rotterdam, Netherlands
NCT Number: NCT07629661
This study protocol describes a type 1 hybrid effectiveness-implementation study evaluating a clinical decision support dashboard for neonatal pain management in a tertiary NICU. Using a pre- and post-implementation design, the study assesses whether the dashboard reduces the duration of inadequately managed neonatal discomfort during the first seven days of admission, while concurrently evaluating implementation outcomes such as acceptability, appropriateness, fidelity, and penetration. Quantitative EHR- and dashboard-derived data are complemented by qualitative interviews and observations to provide a comprehensive evaluation of both clinical impact and implementation processes.
This study is active but is not currently recruiting participants.
Notify MeAll sexes
Interventional
Not applicable
Rotterdam, Netherlands
This protocol outlines a single-center, type 1 hybrid effectiveness-implementation study evaluating an in-house developed clinical decision support dashboard designed to optimize pain management in the Neonatal Intensive Care Unit (NICU). The study is conducted at a level III-IV NICU and follows a pre-implementation (retrospective), mid-implementation, buffer, and post-implementation (prospective) design over approximately 26 months.
The primary effectiveness objective is to determine whether implementation of the dashboard reduces the duration of inadequately managed neonatal discomfort during the first seven days of admission. Discomfort is operationalized as the cumulative duration a neonate is classified as "red" by the dashboard prioritization algorithm, indicating the need for immediate clinical attention. Pre-implementation "red" classifications are generated retrospectively from electronic health record data using the same algorithmic criteria applied prospectively post-implementation.
The secondary objective is to evaluate the implementation process of the dashboard within routine NICU workflows. Implementation outcomes, based on the framework of Proctor et al., include acceptability, appropriateness, fidelity (implementation and effectiveness), and penetration. These outcomes are assessed using a mixed-methods approach, combining quantitative measures such as dashboard use metrics, prescribing patterns, and timing of pain assessments with qualitative data from semi-structured interviews and observations involving healthcare professionals and parents.
The comfort-dashboard is implemented using a phased ward-based approach supported by targeted training, local champions, and ongoing facilitation. The study poses minimal risk, as the dashboard supports but does not replace clinical decision-making, and no changes are made to core algorithm logic or outcome definitions during the study. By integrating effectiveness and implementation evaluations, this protocol aims to generate clinically relevant evidence while supporting reproducibility, transparency, and future scalability of digital decision support tools in neonatal care.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Primary endpoint - Effectiveness evaluation (neonates):
Secondary endpoints - Implementation process evaluation (healthcare professionals):
Secondary endpoints - Implementation process evaluation (parents):
Primary endpoint - Effectiveness evaluation (neonates):
Secondary endpoints - Implementation process evaluation:
The comfort-dashboard designed to assist healthcare professionals in managing neonatal pain within the Neonatal Intensive Care Unit (NICU). The software aggregates and visualizes patient-specific data from connected systems, providing near-real-time metrics, patient prioritization, and clinical decision support.
Time frame: Days 1-7 of NICU admission, assessed through study completion (approximately 13 months post go-live, November 2026).
For the primary aim of our study, we will assess the effectiveness of the dashboard in improving the comfort of patients admitted to the NICU, defined by the difference in the duration of inadequately managed discomfort in neonates during the first seven days of admission. Here, the duration of inadequately managed discomfort is measured by the duration a patient has a 'red' status, as classified by the classification algorithm.
Time frame: At 6 months post go-live (week 32-35)
The SUS is a 10-item standardized questionnaire administered to healthcare professionals. Each item is rated 1-5. Odd-numbered item scores are reversed; all scores are summed and multiplied by 2.5 to yield a normalized score (range 0-100; higher = better usability). The SUS score is interpreted as a percentile rank.
Time frame: At 6 months post go-live (week 32-35)
Semi-structured interviews exploring perceived barriers and facilitators to implementation, usefulness, ease of use, and overall satisfaction with TMD-C, conducted with healthcare professionals and parents. Analysis uses direct content analysis guided by the Consolidated Framework for Implementation Research (CFIR).
Time frame: Through study completion, ~13 months
Perceived fit, relevance, and compatibility of the chosen implementation strategies, assessed through semi-structured interviews and systematic observations with healthcare professionals, analyzed using CFIR constructs.
Time frame: Weeks 0-7 (mid-implementation phase)
Implementation fidelity measure: the proportion of healthcare professionals working in the NICU during the study period who attended at least one TMD-C training session.
Time frame: Days 1-7 of admission through study completion, ~13 months
The difference in the proportion of therapy initiations and dose-escalation events accompanied by a loading dose within the protocol-specified timeframe, comparing pre- and post-implementation phases, stratified by moment (initiation vs. escalation).
Time frame: Days 1-7 of admission, through study completion (approximately 13 months post go-live)
The difference in the duration of continuous analgesic infusion in neonates classified as not experiencing discomfort, comparing pre- and post-implementation phases, stratified by drug and relevant patient characteristics.
Time frame: Days 1-7 of admission, through study completion (approximately 13 months post go-live)
The difference in starting dosage and height of subsequent dose escalation steps surrounding dose-escalation events, comparing pre- and post-implementation phases, stratified by drug and relevant patient characteristics.
Time frame: Days 1-7 of admission, through study completion (approximately 13 months post go-live)
The difference in the cumulative duration a patient is classified as oversedated, comparing pre- and post-implementation phases.
Time frame: Days 1-7 of admission, through study completion (approximately 13 months post go-live)
The difference in the proportion of pain measurements conducted within the protocol-specified timeframe after therapy initiation, dose-escalation, dose-decrease, and therapy discontinuation, comparing pre- and post-implementation phases, stratified by relevant patient characteristics.
Time frame: Through study completion, approximately 13 months post go-live
The frequency of TMD-C access during morning rounds, used as a measure of penetration - the extent to which dashboard use has become part of routine NICU workflow.
Time frame: Through study completion, ~ 13 months
Descriptive statistic for included neonates. Reported for both pre- and post-implementation cohorts.
Time frame: Through study completion, ~ 13 months
Descriptive statistic for included neonates. Expressed as mean (±SD) or median (±IQR) depending on data distribution. Reported for both pre- and post-implementation cohorts.
Time frame: Through study completion, ~ 13 months
Descriptive statistic for included neonates. Expressed as mean (±SD) or median (±IQR) depending on data distribution. Reported for both pre- and post-implementation cohorts.
Time frame: Through study completion, ~ 13 months
Descriptive statistic for healthcare professionals participating in the implementation evaluation. Categories include physician, nurse, nurse specialist, and management. Reported for the post-implementation cohort.
Time frame: Through study completion, ~ 13 months
Descriptive statistic for healthcare professionals. Expressed as mean (±SD) or median (±IQR) depending on data distribution. Reported for the post-implementation cohort.
Erasmus Medical Center
Other
A Hybrid Effectiveness-implementation Study on the Implementation of a Clinical Pain Management Dashboard for the NICU
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT02979574
Agnosia, Chronic Pain
Basking Ridge, New Jersey, United States
View Trial DetailsNCT07247565
Agnosia, Nervous System Diseases
Cairo, Egypt
View Trial DetailsNCT07016386
Agnosia, Nervous System Diseases
Giza, Giza Governorate, Egypt
View Trial DetailsNCT06629727
Agnosia, Anxiety Disorders
Istanbul, Turkey (Türkiye)
View Trial Details